Patents Assigned to Novartis Vaccines and Diagnostics, Inc.
  • Patent number: 8796211
    Abstract: The present invention provides a unit dose composition comprising 0.2 ?g/kg to 48 ?g/kg of an FGF-2 of SEQ ID NO:2, or an angiogenically active fragment or mutein thereof in a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into one or more coronary vessels or a peripheral vein of said patient a safe and angiogenically effective dose of a recombinant FGF-2, or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising a therapeutically effective amount of FGF-2, alone or in combination with heparin, in a therapeutically effective carrier.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: August 5, 2014
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventor: Martha Jo Whitehouse
  • Publication number: 20140205602
    Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.
    Type: Application
    Filed: December 19, 2013
    Publication date: July 24, 2014
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Li Long, Mohammad Luqman, Asha Yabannavar, Isabel Zaror, Sang Hoon Lee, Deborah Hurst
  • Patent number: 8778358
    Abstract: The invention relates to the identification of a new adhesin islands within the genomes of several Group A and Group B Streptococcus serotypes and isolates. The adhesin islands are thought to encode surface proteins which are important in the bacteria's virulence. Thus, the adhesin island proteins of the invention may be used in immunogenic compositions for prophylactic or therapeutic immunization against GAS or GBS infection. For example, the invention may include an immunogenic composition comprising one or more of the discovered adhesin island proteins.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: July 15, 2014
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: John Telford, Guido Grandi, Immaculada Margarit Y Ros, Cira Daniela Rinaudo, Domenico Maione
  • Patent number: 8771747
    Abstract: Microparticles with adsorbent surfaces, methods of making such microparticles, and uses thereof, are disclosed. The microparticles comprise a polymer, such as a poly(?-hydroxy acid), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, and the like, and are formed using cationic, anionic, or nonionic detergents. The surface of the microparticles efficiently adsorb biologically active macromolecules, such as DNA, polypeptides, antigens, and adjuvants. Also provided are compositions of an oil droplet emulsion having a metabolizable oil and an emulsifying agent. Immunogenic compositions having an immunostimulating amount of an antigenic substance, and an immunostimulating amount of an adjuvant composition are also provided.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: July 8, 2014
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Derek O'Hagan, Gary S. Ott, John Donnelly, Jina Kazzaz, Mildred Ugozzoli, Manmohan Singh, John Barackman
  • Patent number: 8772255
    Abstract: Compositions incorporating small interfering ribonucleic acid (siRNA) and certain lipid-conjugated polyamide compound-based delivery vehicles that are particularly useful in the delivery siRNA and other polynucleotides to cells. Also, methods of making and using the compositions.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: July 8, 2014
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Timothy S. Burkoth, Anne B. Jefferson, Christoph Reinhard, Ronald N. Zuckermann
  • Publication number: 20140161887
    Abstract: Adjuvant compositions comprising type 1 interferon inducers, such as double-stranded RNA, in combination with antigen delivery systems and/or immunostimulatory molecules, such as immunostimulatory nucleic acid sequences, for enhancing the immune response of a coadministered antigen, are described.
    Type: Application
    Filed: November 15, 2013
    Publication date: June 12, 2014
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Derek O'Hagan, Nicholas Valiante
  • Patent number: 8735599
    Abstract: The present invention relates to new substituted imidazole compounds and pharmaceutically acceptable salts, esters or prodrugs thereof, compositions of the new compounds together with pharmaceutically acceptable carriers, and uses of the new compounds.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: May 27, 2014
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Weibo Wang, Paul A. Barsanti, Xia Yia, Rustum S. Boyce, Sabina Pecchi, Nathan Brammeier, Megan C. Phillips, Kris Mendenhall, Kelly Wayman, Liana Marie Lagnition, Ryan N. Constantine, Hong Yang, Elizabeth Mieuli, Savithri Ramurthy, Elisa Jazan, Anu Sharma, Rama Jain, Sharadha Subramanian, Paul A. Renhowe, Kenneth W. Bair, David Duhl, Annette Walter, Tinya Abrams, Kay Huh, Eric Martin, Mark Knapp, Vincent P. Le
  • Publication number: 20140142038
    Abstract: The present invention provides a unit dose comprising 0.2 ?g/kg to 36 ?g/kg of a recombinant FGF or an angiogenically active fragment or mutein thereof. Also provided is a pharmaceutical composition comprising an angiogenically effective dose of an FGF or an angiogenically active fragment or mutein thereof, and a pharmaceutically acceptable carrier. Also provided is a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of said patient a safe and angiogenically effective dose of a recombinant FGF of any of SEQ ID NOS:1-3, 5, 8-10, or 12-14, or an angiogenically active fragment or mutein thereof.
    Type: Application
    Filed: December 6, 2013
    Publication date: May 22, 2014
    Applicant: NOVARTIS VACCINES AND DIAGNOSTICS, INC.
    Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
  • Publication number: 20140135384
    Abstract: HERV-K human endogenous retroviruses show up-regulated expression in tumors. In particular, splicing events in the env region generate a series of transcripts which utilize the +2 reading frame, relative to the env reading frame. The proteins show activity typical of transcriptional regulators, and they also have oncogenic potential. Two related proteins, PCAP2 and PCAP3, are strongly associated with breast cancer and prostate cancer, respectively. PCAP4 stimulates cell division. These proteins can be used in cancer diagnosis and therapy, and are also drug targets e.g. for adjuvant therapy. The identification of these splice products is remarkable because full sequence information has been available for HERV-K viruses since 1986.
    Type: Application
    Filed: January 15, 2014
    Publication date: May 15, 2014
    Applicant: NOVARTIS VACCINES & DIAGNOSTICS, INC.
    Inventors: Pablo GARCIA, Stephen F. HARDY, Lewis T. WILLIAMS, Jaime ESCOBEDO
  • Publication number: 20140099719
    Abstract: Mosaic VLPs of viral capsid proteins from different virus types are described, as are methods of making the same. Specifically, a diploid yeast strain that coexpresses the L1 and L2 capsid proteins of both HPV-6 and HPV-16 as mosaic VLPs is described. The mosaic VLPs induced the production of conformational antibodies against both L1 proteins upon administration to mice.
    Type: Application
    Filed: May 14, 2013
    Publication date: April 10, 2014
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Daniela Tornese Buonamassa, Catherine E. Greer, Cesira L. Galeotti, Giuliano Bensi, Roberto Petracca
  • Patent number: 8637032
    Abstract: Compositions and methods of therapy for treating diseases mediated by stimulation of CD40 signaling on CD40-expressing cells are provided. The methods comprise administering a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity, but exhibits antagonist activity when the antibody binds a CD40 antigen on a human CD40-expressing cell. Antagonist activity of the anti-CD40 antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of human CD40-expressing cells, such as B cells.
    Type: Grant
    Filed: September 12, 2012
    Date of Patent: January 28, 2014
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Li Long, Asha Yabannavar, Isabel Zaror, Sang Hoon Lee, Deborah Hurst
  • Publication number: 20140004140
    Abstract: This application relates to improved Group B Streptococcus (“GBS”) saccharide-based vaccines comprising combinations of GBS polysaccharides with polypeptide antigens, and vice versa, such that the polypeptide and the saccharide each contribute to the immunological response in a recipient. The combination is particularly advantageous where the saccharide and polypeptide are from different GBS serotypes. The combined antigens may be present as a simple combination where separate saccharide and polypeptide antigens are administered together, or they may be present as a conjugated combination, where the saccharide and polypeptide antigens are covalently linked to each other.
    Type: Application
    Filed: September 6, 2013
    Publication date: January 2, 2014
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Rino Rappuoli, John Telford, Guido Grandi
  • Patent number: 8618052
    Abstract: The present invention is directed to a method for treating a human patient for coronary artery disease, comprising administering into at least one coronary vessel of a human patient in need of treatment for coronary artery disease a safe and angiogenically effective dose of a recombinant FGF-5 of SEQ ID NO:9, or an angiogenically active fragment or mutein thereof. The invention is also directed to a method for inducing angiogenesis in the heart of a patient, comprising administering into at least one coronary vessel of a human patient in need of coronary angiogenesis a therapeutically effective amount of a recombinant FGF-5 of SEQ ID NO:9, or an angiogenically active fragment or mutein thereof.
    Type: Grant
    Filed: November 17, 2010
    Date of Patent: December 31, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Martha J. Whitehouse, W. Michael Kavanaugh
  • Patent number: 8614330
    Abstract: New substituted benz-azole compounds, compositions and methods of inhibition of Raf kinase activity in a human or animal subject are provided. The new compounds compositions may be used either alone or in combination with at least one additional agent for the treatment of a Raf kinase mediated disorder, such as cancer.
    Type: Grant
    Filed: March 12, 2010
    Date of Patent: December 24, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: Payman Amiri, Wendy Fantl, Teresa Hansen, Barry Haskell Levine, Christopher McBride, Daniel J. Poon, Savithri Ramurthy, Paul A. Renhowe, Cynthia M. Shafer, Sharadha Subramanian, Leonard Sung
  • Patent number: 8609109
    Abstract: Provided herein are HIV vaccines comprising HIV polypeptide-encoding DNA adsorbed to PLG and/or HIV proteins. Also provided are methods of using these vaccines to generate immune responses in a subject.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: December 17, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventors: John Donnelly, Susan W. Barnett, Derek O'Hagan
  • Publication number: 20130315951
    Abstract: The invention provides for oral compositions for safely stimulating an immune response to mucoadhesive antigens for protection against infectious agents, particularly influenza viruses using heat-labile, mutant Escherichia coli enterotoxins and antigen. Methods of stimulating immune responses and for eliciting IgA antibodies are also provided.
    Type: Application
    Filed: November 6, 2012
    Publication date: November 28, 2013
    Applicant: Novartis Vaccines and Diagnostics, Inc.
    Inventors: John D. Barackman, Gary Ott, Samuel Pine, Derek O'hagan
  • Patent number: 8568734
    Abstract: Fusion proteins comprising CD4 minimal modules that bind to HIV Env polypeptides in a non-CD4 backbone are described. Also described are complexes of these fusion proteins with Env as well as methods of diagnosis, treatment and prevention using the polynucleotides and polypeptides are also provided.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: October 29, 2013
    Assignee: Novartis Vaccines and Diagnostics Inc.
    Inventors: Vega Masignani, Maria Scarselli, Barbara Capecchi, Victoria Sharma, Susan W Barnett, Indresh K. Srivastava, Rino Rappuoli
  • Patent number: 8551706
    Abstract: West Nile virus capture oligonucleotides, primers and probes derived from conserved regions of the West Nile virus genome are disclosed. Also disclosed are nucleic acid-based assays using the capture oligonucleotides, primers and probes.
    Type: Grant
    Filed: April 15, 2011
    Date of Patent: October 8, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventor: Venkatakrishna Shyamala
  • Patent number: 8541230
    Abstract: The present invention relates to polynucleotides encoding immunogenic HIV type C Gag- and/or Env-containing polypeptides. Uses of the polynucleotides in applications including DNA immunization, generation of packaging cell lines, and production of Gag- and/or Env-containing proteins are also described.
    Type: Grant
    Filed: May 16, 2011
    Date of Patent: September 24, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc
    Inventors: Susan W. Barnett, Jan Zur Megede
  • Patent number: 8541023
    Abstract: Immunogenic compositions containing phospholipid adjuvants, including microparticle and emulsion compositions. According to one aspect of the invention, an immunogenic microparticle composition is provided comprising: water; a polymer microparticle; an antigen adsorbed to the microparticle; and a phospholipid compound, e.g., a synthetic phospholipid compound comprising: (i) one or more phosphoryl groups independently selected from a phosphato group and a phosphodiester group; (ii) a plurality of linear alkane groups. According to another aspect of the invention an immunogenic emulsion composition is provided that comprises: water; a metabolizable oil; an emulsifying agent; an antigen; and a phospholipid compound, e.g., a synthetic phospholipid compound like that above. The emulsion composition is an oil-in-water emulsion having oil and aqueous phases, in which the oil phase is in the form of oil droplets, substantially all of which are less than 1 micron in diameter.
    Type: Grant
    Filed: October 10, 2011
    Date of Patent: September 24, 2013
    Assignee: Novartis Vaccines and Diagnostics, Inc.
    Inventor: Derek O'Hagan